About: Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
Creator	Toumi, Mondher Aballea, Samuel
Source	Medline; PMC
abstract	The results of a clinical trial comparing hydroxychloroquine with or without azithromycin to the standard of care for the treatment of COVID-19 were recently published by Philippe Gautret et al. This study provides outstanding results for the combination of hydroxychloroquine and azithromycin over the standard of care, but the evidence was deemed insufficiently robust to warrant a public health decision to widen the use of hydroxychloroquine for the treatment of COVID-19. We provide a scientific critical review of the Gautret et al. publication, put the results in the context of the current knowledge, provide an evaluation of the validity of the results (from a methodologic perspective), and discuss public health implications. The study has a number of limitations, including small sample size, lack of comparability between patients in active treatment and control arms, lack of blinding, use of interim analyses without controlling for the risk of type 1 error, use of analysis in the per-protocol population instead of the intention-to-treat population, and inconsistencies between the study protocol and article. However, none of these observations is of a nature to reverse the conclusions. The study brings useful knowledge consistent with available evidence and clinical practice from China and South Korea, which could have prompted quicker policy decision-making.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1080/20016689.2020.1758390
bibo:pmid	32537099
has license	cc-by-nc
sha1sum (hex)	823b889d0a6755ea8bb9a1ccae7717befc06990b
schema:url	https://doi.org/10.1080/20016689.2020.1758390
resource representing a document's title	Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
has PubMed Central identifier	PMC7269042
has PubMed identifier	32537099
schema:publication	J Mark Access Health Policy
resource representing a document's body	covid:823b889d0a6755ea8bb9a1ccae7717befc06990b#body_text
is schema:about of	named entity 'controlling' named entity 'widen' named entity 'azithromycin' named entity 'COVID-19' named entity 'Hydroxychloroquine' named entity 'USE OF' named entity 'LIMITATIONS' named entity 'ARMS' named entity 'WIDEN' named entity 'REVERSE' named entity 'RISK OF' named entity 'PATIENTS' named entity 'BLINDING' named entity 'INTENTION-TO-TREAT' named entity 'TYPE 1' named entity 'PROMPTED' named entity 'CONTROLLING' named entity 'CHINA' named entity 'RESULTS' named entity 'SOUTH KOREA' named entity 'SCIENTIFIC' named entity 'NUMBER OF' named entity 'COMBINATION' named entity 'ROBUST' named entity 'OUTSTANDING' named entity 'PROVIDE' named entity 'analyses' named entity 'public health' named entity 'care' named entity 'policy' named entity 'provide' named entity 'critical review' named entity 'COVID-19' named entity 'Commentary' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'standard of care' named entity 'clinical trial' named entity 'type 1 error' named entity 'clinical practice' named entity 'South Korea' named entity 'intention-to-treat' named entity 'public health' named entity 'azithromycin' named entity 'hydroxychloroquine' named entity 'Shanghai' named entity 'decision-making' named entity 'pneumonia' named entity 'Evidence-based medicine' named entity 'clinical trials' named entity 'hydroxychloroquine' named entity 'bacterial infection' named entity 'standard of care' named entity 'France' named entity 'randomly assigned' named entity 'Evidence-based medicine' named entity 'RNA' named entity 'azithromycin' named entity 'intensive care unit' named entity 'adverse events' named entity 'chloroquine' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'malaria' named entity 'clinical trial' named entity 'missing data' named entity 'France' named entity 'prognosis' named entity 'azithromycin' named entity 'decision-makers' named entity 'HIV' named entity 'body weight' named entity 'selection bias' named entity 'effect size' named entity 'chloroquine' named entity 'coronavirus 2' named entity 'prophylactic treatment' named entity 'hydroxychloroquine' named entity 'ritonavir' named entity 'hydroxychloroquine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software